Shionogi & Co. Ltd. (4507.TO) Osaka 1st Quarter Ended June 30 GROUP 2025 2024 Revenue Y99.78 bln Y97.59 bln Operating Profit Y35.10 bln Y28.11 bln Pretax Profit Y46.33 bln Y36.53 bln Net Profit Y39.36 ...

Shionogi & Co ( ($SGIOF) ) has released its Q1 earnings. Here is a breakdown of the information Shionogi & Co presented to its investors. Shionogi ...

Shionogi & Co ( ($JP:4507) ) just unveiled an update. Shionogi & Co., Ltd. announced that ViiV Healthcare presented results from the VOLITION ...

And Shionogi’s agreements with GARDP and CHAI are absolute proof of their commitment to the antibiotic space. For those of you who are interested in antibiotic R&D, I am assured by their CEO that ...

Shionogi & Co. shares fell sharply Thursday morning after a panel at Japan’s Ministry of Health, Labor and Welfare decision yesterday that its pill to treat Covid-19 wasn’t ready for emergency ...

Japan's Shionogi & Co said on Monday its pill-based treatment for COVID-19 did not meet the primary endpoint of showing a statistically significant reduction of 15 common symptoms of the illness ...

TOKYO, April 24 (Reuters) - An experimental treatment from Shionogi & Co Ltd (4507.T), opens new tab has shown rapid clearance of the virus that causes COVID-19, according to new data, the ...

Shionogi & Co.’s experimental Covid-19 treatment Xocova failed to win the backing of health experts in Japan who said there wasn’t enough data to show the medicine’s efficacy.

Shionogi stock is priced as if Xocova sales will only occur for one year then stop, which is quite unlikely. It certainly does not help that global COVID cases are at a new low point since the ...

Shionogi & Co., Ltd. (hereafter “Shionogi”) today announced results from APEKS-NP, an international, double-blind, randomized Phase III clinical t ...

TOKYO -- Shionogi & Co. said Monday it will acquire Atlanta-based Sciele Pharma Inc. in an all-cash deal valued at $1.42 billion, buying sales channels and access to a better clinical-study ...

Shionogi filed for approval in the autumn of 2017. Compared to Tamiflu, which requires two doses each day for five days, apparently only a single dose of Xofluza will be needed to treat the flu.